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Toll-likereceptor3(TLR3)isamemberoftheTLRfamilythatcanrecognizedouble-strandedRNA(dsRNA),playinganimportant
role in antiviral immunity. Recent studies have shown that TLR3 is also expressed on parenchymal and nonparenchymal cells in
the liver as well as on several types of immune cells. In this review, we summarize the role of TLR3 in liver injury, inﬂammation,
regeneration, and liver ﬁbrosis, and discuss the implication of TLR3 in the pathogenesis of human liver diseases including viral
hepatitis and autoimmune liver disease.
1.Introduction
TLR3 is a member of the Toll-like receptor family that
can recognize double-stranded RNA (dsRNA) from viruses,
endogenous dsRNA from dying cells, or synthetic dsRNA
polyriboinosinic:polyribocytidylic acid (poly I:C). TLR3
expression has been found in endosomal compartments
(such as dendritic cells and macrophages) or at the cell
surfaces (such as human ﬁbroblasts). Binding of TLR3 and
its ligand leads to conformational changes in the TLR3
cytoplasmic tail, followed by recruitment of TIR domain-
containing adaptor inducing IFN-β (TRIF), and subsequent
activation of the mitogen activated protein (MAP) kinase
pathway, the NF-κB family of transcription factors, and the
I F Nr e g u l a t o r yf a c t o r( I R F )f a m i l yo ft r a n s c r i p t i o nf a c t o r s ,
which then induce interferon (IFN) and inﬂammatory
cytokine production [1, 2]. It is generally believed that TLR3
plays an important role in host response to viruses via
recognizing dsRNA; however, its role in antiviral immunity
has been questioned by some in vivo studies [3, 4]. The
controversial reports on the role of TLR3 in the antiviral
defense may be due to the diﬀerence in the type of viruses,
the type of cells that are infected, the viral load, its model
of infection (endoplasmic versus cytoplasmic), and stage of
infection. Recent studies have shown that TLR3 also plays
important roles in the pathophysiology of a variety of liver
diseases [5–7], which may attribute to the wide expression of
TLR3 on all types of liver cells, including hepatocytes [8–10],
stellate cells [11], sinusoidal endothelial cells [12], Kupﬀer
cells, biliary epithelial cells [13, 14], as well as immune cells
such as NK cells, NKT cells [15], and liver lymphocytes [12].
In this review, we summarize the recent ﬁndings regarding
the role of TLR3 in liver injury, inﬂammation, regeneration,
ﬁbrosis, viral infection, and autoimmune liver disease.
2. TLR3 inLiverInﬂammation andInjury
It has been noticed for many years that injection of mice
with the TLR3 ligand poly I:C induced signiﬁcantly liver
inﬂammation with a predominant accumulation of NK
cells [16, 17]. Recent studies suggest that such NK cell
accumulation is due to the recruitment of NK cells from
the spleen, which is regulated positively by the expression of
chemokines and the presence of T cells [18], but regulated
negatively by the β2 integrin CD11b [19]. Treatment with
poly I:C induced mild liver injury in normal mice via an
NK cell-dependent manner [20] but induced massive liver
necrosis in D-galactosamine (D-GalN)-sensitized mice [21,
22]. In the model of liver injury induced by poly I:C/D-
GalN, it is believed that injection of these two reagents
elevates the expression of retinoic acid early inducible-1
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cell stimulating ligand to activate NK cells via targeting
NKG2D receptor on NK cells. Activated NK cells then
produce a large amount of IFN-γ, which acts in synergy with
Kupﬀer cell-derived TNF-α to induce massive hepatocellular
damage [22]. In addition, poly I:C treatment also induced
signiﬁcantlyliver injury in transgenic mice withHBVsurface
antigen(HBs-B6)[23,24].ItwasshownthatdepletionofNK
cells or blockage of IFN-γ but not depletion of Kupﬀer cells
or neutralization of IL-12 diminished the poly I:C-induced
liver injury in HBs-B6 mice, suggesting that NK cells/IFN-γ
contributetothepathogenesisofliverinjuryinthismodel.In
contrast to the detrimental eﬀect of poly I:C on liver injury,
pretreatment with poly I:C had a beneﬁcial eﬀect to reduce
the mortality and liver injury induced by lipopolysaccharide
plus D-GalN in mice [25]. This protective eﬀect of poly I:C
seems to be mediated via poly I:C downregulation of TLR4
expression on Kupﬀer cells/macrophages and subsequent
reductionoftheresponsivenessofKupﬀercells/macrophages
to LPS stimulation. In addition, activation of TLR3 on
Vα14 iNKT cells may also negatively regulate liver inﬂam-
mation via preventing intrahepatic γδ T cell accumulation
[15].
Although the eﬀe c to fp o l yI : Co nl i v e ri n j u r yh a s
been extensively investigated, the role of TLR3 signaling
in these eﬀects remains obscure. TLR3-deﬁcient mice had
reduced response to poly I:C stimulation, reduced produc-
tion of inﬂammatory cytokines stimulated by poly I:C, and
resistance to poly I:C/D-GalN-induced mortality, suggesting
a critical role of TLR3 signaling in poly I:C-mediated
liver injury [21]. The important role of TLR3 in liver
inﬂammation and injury has also been recently revealed in
Concanavalin A- (Con A-) induced T cell hepatitis model
by using TLR3-deﬁcient mice [12]. Injection of Con A
markedly increased TLR3 expression on liver lymphocytes
and sinusoidal endothelial cells. Disruption of the TLR3
gene abolished Con A-induced liver injury. Finally, by using
chimeric mice, Xiao et al. [12] demonstrated that TLR3
signaling in both nonhematopoietic and hematopoietic cells
plays a critical role in the pathogenesis of Con A-induced T
cell hepatitis. However, what the endogenous ligands are and
how these ligands activate TLR3 in this Con A-induced T cell
hepatitis model remain unknown.
3. TLR3 in LiverRegeneration
Liver regeneration is a very complicated process orchestrated
with a series of signaling cascades induced by cytokines,
growth factors and hormones [26]. Current knowledge
from experimental studies of liver regeneration suggests that
tissue loss or cell damage triggers innate immune responses
and initiates liver regeneration. Among the multiple innate
components, the role of TLR4 signaling in liver regeneration
has been extensively investigated. However, the results on
the role of TLR4 signaling and its adapter protein myeloid
diﬀerentiation factor-88 (MyD88) in liver regeneration have
been controversial [27, 28]. Early studies showed that
TLR4/MyD88 pathway was critical for the initiation of liver
regeneration [27]. Impaired liver regeneration was observed
in MyD88−/− mice after partial hepatectomy (PHx). This
phenomenon was associated with grossly subnormal induc-
tion of the expression of immediate early genes involved in
hepatocyte replication and the phosphorylation of STAT3
in the liver, and the reduced production of TNF-α/IL-6 by
the activation of NF-κB in the Kupﬀer cells. Surprisingly, a
later report indicated liver regeneration was not suppressed
inmicedeﬁcientinMyD88,TLR2,TLR4,orCD14gene[28].
Although normal hepatocyte DNA replication was observed
inMyd88knockoutmice,PHx-mediatedinductionofproin-
ﬂammatory cytokines TNF-α, IL-6, and their downstream
signaling pathways was reduced in MyD-88 knockout mice
[28]. At present, the reasons for the discrepancy between
these 2 studies are not clear [27, 28]. The diﬀerent surgical
techniques and animal facility environment may contribute
to the diﬀerent ﬁndings on liver regeneration in MyD88
knockout mice.
In contrast, a series of evidence show that TLR3/IFN-
γ/STAT1 axis plays an inhibitory role in liver regeneration,
suggesting that the innate immune system may play an
important role in balancing liver regeneration [29–32].
We have previously demonstrated that after infection with
murine cytomegalovirus (MCMV) or poly(I:C) injection,
NK cells are activated and produce IFN-γ that in turn
attenuates liver regeneration after PHx. Depletion of NK
cells or disruption of either the IFN-γ gene or the IFN-
γ receptor gene enhances liver regeneration and partially
abolishes the negative eﬀects of MCMV and poly(I:C) on
liver regeneration. These results suggest that viral infection
and the TLR3 ligand negatively regulate liver regeneration
via activation of innate immunity (NK/IFN-γ)[ 31]. Con-
sistent with these results of the inhibitory role of TLR3
in liver regeneration, TLR3−/− mice demonstrated earlier
hepatocyteproliferationandanincreasein liverregeneration
following PHx [29]. In the absence of TLR3, hepatocyte
proliferation was accelerated while the levels of IL-6 and
soluble interleukin-6 receptor (sIL-6R) were reduced. TLR3
signaling was induced in hepatocytes at the early time points
after PHx, resulting in enhanced NF-κB activation, the
increase levels of Rip3 and activation of caspase-8, with no
evidence of apoptosis. These ﬁndings suggest TLR3 signaling
plays an important role in inhibiting liver regeneration [29].
We have further demonstrated that IFN-γ inhibits liver
regeneration via activation of STAT1 and subsequent induc-
tion of IRF-1 and p21 [30, 32]. Disruption of the STAT1
gene abolished poly I:C suppression of liver regeneration
and the inhibitory eﬀect of poly I:C on liver regeneration
was diminished in IRF-1−/− and p21cip1−/− mice. Treatment
with IFN-γ in vitro inhibited cell proliferation of wild-
type mouse hepatocytes, but not STAT1−/− hepatocytes. The
inhibitory eﬀect of IFN-γ on cell proliferation was also
diminished in IRF-1−/− and p21cip1−/− hepatocytes, but
enhanced in SOCS1−/− hepatocytes. Hepatocyte prolifera-
tion was unaﬀected by treatment with poly I:C alone, but
when hepatocytes were cocultured with liver lymphocytes,
hepatocyte proliferation was inhibited by IFN-γ/STAT1-
dependent mechanisms. Moreover, in HCV-infected livers
with cirrhosis, activation of STAT1 was detected and cor-
related positively with liver injury but correlated negatively
with hepatocyte proliferation.Gastroenterology Research and Practice 3
4. TLR3 inLiverFibrosis
Liver ﬁbrosis is a common response to virtually all forms of
chronic liver injury and is characterized with hepatic stellate
cell (HSC) activation and accumulation of extracellular
matrix proteins [33, 34]. HSCs are generally believed to
be the most important cells in producing collagens and
contributing to the pathogenesis of liver ﬁbrosis. Activation
of HSCs is controlled by many cytokines and growth factors.
Among them, TGF-β is considered the most important
factor to induce HSC transformation while PDGF plays
a critical role in stimulating HSC proliferation. Recent
studies have also suggested that TLR4 plays an impor-
tant role in promoting liver ﬁbrosis via enhancing TGF-
β signaling in HSCs [35]. Our laboratory has demon-
strated that treatment of mice with the TLR3 ligand poly
I:C markedly inhibits liver ﬁbrosis [36, 37], which was
conﬁrmed later by another laboratory [38]. The studies
from our laboratory as well as other laboratories suggest
that multiple mechanisms contribute to poly I:C-mediated
inhibition of liver ﬁbrosis. First, poly I:C treatment induces
NK cell activation, and activated NK cells then kill early-
activated or senescence-activated HSCs that have increased
expression of NK cell activating ligands [36, 38]; Second,
poly I:C treatment induces NK cells to produce IFN-γ
that subsequently induces HSC apoptosis and cell cycle
arrest [37]. Recent studies from Dr. Schlaak’s laboratory
have shown that poly I:C treatment stimulates HSCs that
e x p r e s sh i g hl e v e l so fT L R 3t op r o d u c et y p eII F N - β [11].
Since type I IFN is known to inhibit HSC proliferation
[39], it is plausible to speculate that activation of TLR3
may also directly block HSC proliferation via production of
IFN-β, thereby contributing to suppression of liver ﬁbrosis.
Furthermore, we have demonstrated that chronic alcohol
consumption suppresses poly I:C-mediated activation of NK
cell activation and induction of cytotoxic mediators on liver
lymphocytes [40] and poly I:C inhibition of liver ﬁbrosis
[41]. Alcohol inhibition of poly I:C-mediated activation
of NK cells is probably mediated via suppression of poly
I:C activation of TLR3 signaling on NK cells [42, 43].
Finally, abrogation of the antiﬁbrotic eﬀect of NK cells
by alcohol may be an important mechanism contributing
to alcohol acceleration of liver ﬁbrosis in patients with
viral infection [41]. We have previously reported that
injection of poly I:C inhibits liver regeneration induced by
partial hepatectomy [31]. Interestingly, a recent paper shows
that injection of poly I:C also inhibits liver regeneration
induced by administration of single dose of CCl4 [44].
However, it is not clear whether poly I:C also has inhibitory
eﬀect on liver regeneration in a model of liver ﬁbrosis
induced by chronic CCl4 treatment, and whether inhibition
of liver regeneration by TLR3 also contributes to liver
ﬁbrogenesis.
5. TLR3 inViralHepatitisInfection
TLR3 is generally believed to play an important role in the
innate immune response against viral infection, including
viral hepatitis infection, although controversial results have
been reported [4]. The antiviral eﬀects of TLR3 signaling on
viral hepatitis infection are likely mediated via stimulating
of a variety of cells to produce type I IFN that subsequently
inhibits HCV or HBV replication [11, 45–47]. These cells
include HSCs [11], monocyte-derived dendritic cells [48],
hepatocytes [47], Kupﬀer cells [46], sinusoidal endothelial
cells [46], NK cells [49], and so forth. Recent studies showed
that TLR3 can also directly sense HCV infection in human
hepatocytes, acting independently of retinoic acid-inducible
gene I (RIG-I), followed by activation of IRF-3 and ISGs
that suppress HCV replication [10]. However, several lines
of evidence suggest that TLR3 signaling is suppressed during
viral hepatitis infection, which may contribute to the escape
of hepatitis virus from the surveillance of innate immunity
and lead to the chronic infection. First, expression of TLR3
and type I IFN was signiﬁcantly decreased in monocyte-
derived dendritic cells from patients with chronic HBV or
acute-on-chronic HBV liver failure compared with normal
healthy individuals. Such reduction correlated positively
with severity of the disease [50]; Second, infection of
hepatoma cells with HCV in vitro degraded TRIF protein,
an essential TLR3 adaptor, and subsequently attenuated
poly I:C-induced signaling [10]; Third, the NS3/4A serine
protease of hepatitis C virus (HCV) can interrupt TLR3
and/or RIG-I-mediated signal transduction by proteolytic
cleavage of TRIF and/or CADIF [51–53]. The TLR3 pathway
plays an important role in inﬂuencing host innate immunity
and viral clearance during viral hepatitis infection, and may
represent a useful therapeutic approach for the treatment
of viral hepatitis. However, a greater understanding of the
speciﬁc cellular source of TLR3 signals and TLR3 pathway
changes in diﬀerent stages of viral infection may assist in the
design of appropriate therapeutic interventions that target
this TLR3 pathway in patients with chronic viral hepatitis
infection.
The association between TLR3 gene polymorphisms
and chronic HCV infection was also recently investigated
[54]. Two single nucleotide polymorphisms (SNPs) were
identiﬁed within the TLR3 gene: rs5743305 (T/A) is located
within the promoter region; rs3775291 (C/T) is located
within exon 4. Both SNPs were not found to be asso-
ciated with TLR3 gene expression in peripheral blood
mononuclear cells (PBMCs); however, a tendency of higher
TLR3 gene expression in the liver was found for exon 4
TT genotypes. No association was found between both
SNPs and the clinical parameters of disease progression
of chronic HCV infection, but the TLR3 exon genotype
was found to be related to resistance to HCV subtype
Ia. These studies suggest that the TLR3 SNP associated
with higher TLR3 expression in the liver might be related
to the resistance to HCV subtype Ia infection but has
no role in disease progression after a chronic infection is
established.
6.TLR3 inAutoimmune LiverDisease
TLR3, together with other endosomal TLRs (TLR7 and
TLR9), have been implicated in the pathogenesis of a
variety of autoimmune diseases [1], including primary4 Gastroenterology Research and Practice
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Figure 1: A model depicting the roles of TLR3 in liver injury, inﬂammation, regeneration, and ﬁbrosis. Poly I:C or dsRNA binds TLR3
receptor in NK cells and stimulates NK cells to produce IFN-γ that induces hepatocyte cell cycle arrest and apoptosis via activation of STAT1.
IFN-γ also induces stellate cell cycle arrest and apoptosis in an STAT1-depdent manner, resulting in inhibition of liver ﬁbrosis. Poly I:C can
also inhibit liver ﬁbrosis via activation of NK cell killing of early activated stellate cells. In addition, poly I:C or dsRNA targets TLR3 in many
other cell types, followed by production of IFNs, chemokines, and anti-inﬂammatory cytokines, resulting in liver inﬂammation.
biliary cirrhosis. The critical role of TLR3 in autoimmune
hepatitis was clearly demonstrated in a model of hepatitis
induced by infection of lymphocytic choriomeningitis virus
(LCMV) [55]. This study suggests that poly I:C activation of
TLR3onantigen-presentationcellssuchasmacrophagesand
dendritic cells produce type I IFN and TNF-α, which then
trigger the release of CXCL9 by hepatocytes, Kupﬀer cells,
endothelial cells, and so forth. CXCL9 then attracts CXCR3
positive self-reactive CD8+ T cells to kill hepatocytes, result-
ing in autoimmune hepatitis. However, the role of TLR3 in
the pathogenesis of human autoimmune diseases is less clear.
Immunohistochemistry analyses showed that the expression
of TLR3 was markedly increased in biliary epithelial cells at
sites of ductular reaction in primary biliary cirrhosis and
autoimmune hepatitis [13, 14]. A strong positive correlation
between the mRNA levels of TLR3 and type I IFN in the
liver was found in the patients with primary biliary cirrhosis,
suggesting TLR3 signaling is involved in the pathogenesis of
primary biliary cirrhosis [14]. In animal models, injection
of poly I:C induced primary biliary cirrhosis-like cholangitis
(such as inﬁltration of mononuclear cells and elevation of
AMA autoantibodies) in a genetically susceptible mouse
strain of female C57BL/6 mice [56, 57]. At present, the
mechanisms by which poly I:C treatment induces cholangitis
remain obscure. It is believed that poly I:C activation of
TLR3signalinginbiliaryepithelialcellsaswellashepatocytes
and immune cells in the liver results in production of type
I IFN, which subsequently contributes to the pathogenesis
of primary biliary cirrhosis [13, 14, 58] .H o w e v e r ,ar e c e n t
study suggests that poly I:C induction of type I IFN in biliary
epithelialcellsismediatedviatargetingRIG-Iandmelanoma
diﬀerentiation-associated gene 5 (MDA5), not TLR3 [13].
Further studies are required to clarify the role of TLR3 in
primary biliary cirrhosis.
In summary, TLR3 is expressed on parenchymal and
nonparenchymal cells in the liver as well as in many types
of immune cells including macrophages, dendritic cells, NK
cells, NKT cells, and so forth (see Figure 1). In general,
activation of TLR3 by dsRNA induces NK cell accumulation
and activation in the liver, leading to liver inﬂammation
and injury. TLR3 signaling also negatively regulates liver
regeneration via stimulating NK cells to produce IFN-γ that
subsequently induces hepatocyte death and cell cycle arrest
via an STAT1-dependent manner. Activation of NK cells by
the TLR3 ligand poly I:C inhibits liver ﬁbrosis via killing
of activated stellate cells and producing IFN-γ that subse-
quently induces stellate cell apoptosis and inhibits stellate
cell proliferation. Clinical studies suggest that TLR3 may
contribute to the resistance to HCV subtype Ia infection but
seems to have no role in disease progression after a chronic
infection is established. TLR3 has also been implicated in
the autoimmune liver disease in animal models, but more
studies are required to clarify the role of TLR3 in human
autoimmune diseases.Gastroenterology Research and Practice 5
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